365 related articles for article (PubMed ID: 22269772)
41. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
42. Melanoma antigens recognised by CD8+ and CD4+ T cells.
Storkus WJ; Zarour HM
Forum (Genova); 2000; 10(3):256-70. PubMed ID: 11007933
[TBL] [Abstract][Full Text] [Related]
43. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
44. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
45. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
46. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
47. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
Larrieu P; Ouisse LH; Guilloux Y; Jotereau F; Fonteneau JF
Cancer Immunol Immunother; 2007 Oct; 56(10):1565-75. PubMed ID: 17318652
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.
Srinivas O; Larrieu P; Duverger E; Boccaccio C; Bousser MT; Monsigny M; Fonteneau JF; Jotereau F; Roche AC
Bioconjug Chem; 2007; 18(5):1547-54. PubMed ID: 17602511
[TBL] [Abstract][Full Text] [Related]
49. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy.
Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH
Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632
[TBL] [Abstract][Full Text] [Related]
50. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
51. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.
Van Nuffel AM; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
Cancer Immunol Immunother; 2012 Jul; 61(7):1033-43. PubMed ID: 22159452
[TBL] [Abstract][Full Text] [Related]
52. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.
Durán-Aniotz C; Segal G; Salazar L; Pereda C; Falcón C; Tempio F; Aguilera R; González R; Pérez C; Tittarelli A; Catalán D; Nervi B; Larrondo M; Salazar-Onfray F; López MN
Cancer Immunol Immunother; 2013 Apr; 62(4):761-72. PubMed ID: 23242374
[TBL] [Abstract][Full Text] [Related]
53. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Moeller I; Spagnoli GC; Finke J; Veelken H; Houet L
Cancer Immunol Immunother; 2012 Nov; 61(11):2079-90. PubMed ID: 22562379
[TBL] [Abstract][Full Text] [Related]
54. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
55. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
56. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
57. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
de Vries IJ; Bernsen MR; Lesterhuis WJ; Scharenborg NM; Strijk SP; Gerritsen MJ; Ruiter DJ; Figdor CG; Punt CJ; Adema GJ
J Clin Oncol; 2005 Aug; 23(24):5779-87. PubMed ID: 16110035
[TBL] [Abstract][Full Text] [Related]
58. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.
Schuurhuis DH; Verdijk P; Schreibelt G; Aarntzen EH; Scharenborg N; de Boer A; van de Rakt MW; Kerkhoff M; Gerritsen MJ; Eijckeler F; Bonenkamp JJ; Blokx W; van Krieken JH; Boerman OC; Oyen WJ; Punt CJ; Figdor CG; Adema GJ; de Vries IJ
Cancer Res; 2009 Apr; 69(7):2927-34. PubMed ID: 19318559
[TBL] [Abstract][Full Text] [Related]
59. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
60. Activated monocytes prime naïve T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo.
Laumbacher B; Gu S; Wank R
Scand J Immunol; 2012 Mar; 75(3):314-28. PubMed ID: 21995310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
